AbbVie puts up $105M for Tizona's preclinical I/O drug

AbbVie has paid $105 million upfront to secure exclusive global rights to Tizona's Therapeutics' research into CD39-targeted therapies, including the preclinical antibody TTX-030. AbbVie will also invest an unspecified sum in Tizona equity, and has lined up development and commercial milestone payments.